FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mo ...

The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025. Tirzepatide is the ...

On the plus side, the time that tirzepatide will stay under review at the FDA has just gotten shorter, as the FDA has granted the drug fast-track review that means it should make a decision within ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...

Tirzepatide (Mounjaro) is available on the NHS as a possible treatment for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity, in adults if they have: a ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

In SURMOUNT‑1 and SURMOUNT‑2, 2,519 people had tirzepatide alone or in combination with other glucose-lowering medicines. The most frequently reported adverse reactions were gastrointestinal disorders ...